Ong SE, Schenone M, et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4617-22. Epub 2009 Mar 2.
Margolin AA, Ong SE, Schenone M, et al. Empirical Bayes analysis of quantitative proteomics experiments. PLoS One. 2009 Oct 14;4(10):e7454.
Raj L, Ide T, Gurkar AU, Foley M, Schenone M, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011 Jul 3;475(7355):231-4. doi: 10.1038/nature10167.
Ong SE, Li X, Schenone M, Schreiber SL, Carr SA., Identifying Cellular Targets of Small-Molecule Probes and Drugs with Biochemical Enrichment and SILAC. Methods Mol Biol. 2012;803:129-40.
Monica Schenone, Ph.D.
Monica Schenone is the technical and scientific leader of the biochemical target identification efforts within the Proteomics Platform as well as a key leader of the overall target identification effort at the Broad. Schenone, who joined the Broad Institute in 2006, uses state-of-the-art proteomic techniques to identify protein targets that bind to drugs and drug-like molecules to understand their mechanism of action and potential use in disease therapy.
At the Broad Institute, Schenone combines her knowledge of chemistry, biochemistry and mass spectrometry, to study not only small-molecule-protein interactions but also protein-protein interactions, to elucidate mechanism of action and pathways involved in early drug discovery efforts. In collaboration with other members of the Proteomics Platform, Schenone developed a method of applying a quantitative mass-spectrometry method called SILAC to study the mechanism of action of small molecules. The platform now works with both Broad and external collaborators to use SILAC target identification analysis for a variety of projects.
Before joining the Broad Institute, Schenone completed training at Children’s Hospital Boston where she worked briefly in the hospital’s proteomics laboratory. She completed her postdoctoral research at Beth Israel Deaconess Medical Center and Harvard Medical School in the department of hemostasis and thrombosis.
Schenone received her Lic. in chemistry from the Universidad de Buenos Aires, Argentina and her Ph.D. in biochemistry from the University of Notre Dame in South Bend, Indiana.